"The Report PharmaPoint:
Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024
provides information on pricing, market analysis, shares, forecast,
and company profiles for key industry participants. -
MarketResearchReports.biz"
Keratoconjunctivitis sicca is a
condition that arises when the eye is not able to produce enough
tears or any tears produced evaporate quickly. The condition occurs
among humans but is also observed to affect some animals. It is due
to these attributes of the condition that it is also referred to as
the dry eye syndrome (DES). Medical practitioners say that this is
the most common type of eye disease, with prevalence rising in
postmenopausal women and the elderly. Being a disease with such a
widespread prevalence, there is a correspondingly high demand for
drugs and therapies to treat the dry eye syndrome. A new report that
is now available on the website of MarketResearchReports.biz, titled
‘PharmaPoint: Dry
Eye Syndrome
- Global Drug Forecast and Market Assessment To 2024,’ studies this
market in detail. The report will help readers track sales of dry eye
syndrome therapeutics worldwide during the period from 2014-2024.
People suffering from this
condition may experience signs and symptoms such as gritty eye
irritation, dryness, burning, and stringy discharge from the eye. As
a result, patients are likely to suffer from problems such as tear
film instability, ocular discomfort, and visual disturbances. If not
treated in time, the condition can cause considerable damage to the
ocular surface.
While the demand for therapeutics
to treat dry eye syndrome continues to remain steady, there has been
little activity in the market by way of new therapeutics launches
over the last ten years. Overall, the availability of treatment
options has not kept pace with the increase in demand. Japan is an
exception with the launch of two therapies – Diquas (2010) and
Mucosta (2013) – which were launched on the market.
The report states that the dearth
of treatment options will soon be addressed with the launch of new
drugs that are in the pipeline. The new DES drugs will be launched
during the forecast period of the report and will drive the market
for dry eye syndrome drugs in the nine major markets of the world.
Already, the launch of drugs such as Ikervis in Europe in 2015 has
begun to change the shape of this market. Moreover, market approvals
have been sought for Restasis and Diquas in other countries. These
developments will induce growth in the dry eye syndrome drugs market.
View
Press Release :
http://www.marketresearchreports.biz/pressrelease/784
Population aging will be yet
another massive driver for the dry eye syndrome market; these
epidemiological changes will spur the demand for drugs and therapies
to treat the dry eye syndrome. The report further investigates which
unmet needs exist in the market and makes recommendations to players
for the monetization of the same.
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment